EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease

George Bakris, Cindy Chen, Alicia K Campbell, Veronica Ashton, Lloyd Haskell, Mukul Singhal

American Journal of Hypertension · 15.05.2024 · 37 (6) · 438-446

DOI: 10.1093/ajh/hpae020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hypertension, online erschienen am 04.03.2024. Verfasst von George Bakris und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Chicago Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension, Renal Insufficiency, Chronic, Blood Pressure. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Scientific Affairs, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Chronic kidney disease (CKD) is a common comorbidity in patients with apparent treatment-resistant hypertension (aTRH). We assessed clinical outcomes, healthcare resource utilization events, and costs in patients with aTRH or difficult-to-control hypertension and stage 3–4 CKD with uncontrolled vs. controlled BP. METHODS This retrospective cohort study used linked IQVIA Ambulatory EMR–US and IQVIA PharMetrics Plus claims databases. Adult patients had claims for ≥3 antihypertensive medication classes within 30 days between 01/01/2015 and 06/30/2021, 2 office BP measures recorded 1–90 days apart, ≥1 claim with ICD-9/10-CM diagnosis codes for CKD 3/4, and ≥1 year of continuous enrollment. Baseline BP was defined as uncontrolled (≥130/80 mm Hg) or controlled (<130/80 mm Hg) BP. Outcomes included risk of major adverse cardiovascular events plus (MACE+; stroke, myocardial infarction, heart failure hospitalization), end-stage renal disease (ESRD), healthcare resource utilization events, and costs during follow-up. RESULTS Of 3,966 patients with stage 3–4 CKD using ≥3 antihypertensive medications, 2,479 had uncontrolled BP and 1,487 had controlled BP. After adjusting for baseline differences, patients with uncontrolled vs. controlled BP had a higher risk of MACE+ (HR [95% CI]: 1.18 [1.03–1.36]), ESRD (1.85 [1.44–2.39]), inpatient hospitalization (rate ratio [95% CI]: 1.35 [1.28–1.43]), and outpatient visits (1.12 [1.11–1.12]) and incurred higher total medical and pharmacy costs (mean difference [95% CI]: $10,055 [$6,741–$13,646] per patient per year). CONCLUSIONS Patients with aTRH and stage 3–4 CKD and uncontrolled BP despite treatment with ≥3 antihypertensive classes had an increased risk of MACE+ and ESRD and incurred greater healthcare resource utilization and medical expenditures compared with patients taking ≥3 antihypertensive classes with controlled BP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsHypertensionRenal Insufficiency, ChronicBlood PressureDrug ResistanceHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeAdultTime FactorsHealth Care CostsDatabases, FactualDrug Costs

Stichwörter der Autor:innen

blood pressureblood pressure controlchronic kidney diseasehealth economicshypertensionreal-world analysistreatment-resistant hypertension

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • University of Chicago Medicine, Chicago, Illinois, USA.
  • Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Janssen Research & Development, LLC, Raritan, New Jersey, USA.

Förderung

  • Janssen Scientific Affairs, LLC

Zitieren

APA

Bakris, G., Chen, C., Campbell, A. K., Ashton, V., Haskell, L., & Singhal, M. (2024). Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease. American Journal of Hypertension, 37(6), 438-446. https://doi.org/10.1093/ajh/hpae020

Vancouver

Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease. American Journal of Hypertension. 2024;37(6):438-446. doi:10.1093/ajh/hpae020

BibTeX
@article{Bakris2024,
  author = {Bakris, George and Chen, Cindy and Campbell, Alicia K and Ashton, Veronica and Haskell, Lloyd and Singhal, Mukul},
  title = {Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease},
  journal = {American Journal of Hypertension},
  year = {2024},
  volume = {37},
  number = {6},
  pages = {438--446},
  doi = {10.1093/ajh/hpae020}
}
Kostenlos starten →